(Q37074311)

English

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

scientific article published on 22 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

15

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

William G Wierda

10

object named as

William Wierda

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

4

object named as

Tapan Kadia

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

14

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

3

object named as

Elias Jabbour

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

Gautam Borthakur

5

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

9

object named as

Sherry Pierce

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

Guillermo Garcia-Manero

16

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

Marina Konopleva

6

object named as

Marina Konopleva

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

Jorge Eduardo Cortes

13

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

Naveen Pemmaraju

7

object named as

Naveen Pemmaraju

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Courtney D DiNardo

1

object named as

Courtney D DiNardo

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

2

object named as

Naval Daver

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Carlos B Bueso-Ramos

11

object named as

Carlos Bueso-Ramos

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

12

object named as

Keyur P Patel

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Hui Yang

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

publication date

22 December 2014

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

The Lancet. Haematology.

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

e12-20

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Prognostic factors and risk models in myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Biology and treatment of the 5q- syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

29 September 2017

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

27 June 2018

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

27 June 2018

Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

4 September 2018

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

4 September 2018

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

4 September 2018

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

4 September 2018

Myelodysplastic Syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4936479

4 December 2018

Myelodysplastic syndrome is not merely "preleukemia"

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2814%2900026-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of lenalidomide on the functional properties of human mesenchymal stromal cells

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2814%2900026-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2814%2900026-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2814%2900026-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2814%2900026-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/26687423

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S2352-3026(14)00026-X

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37074311&oldid=2123426989"